Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAIL Trial: Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-resistant Ovarian Cancer
2014-005251-39Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Mar 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lurbinectedin in ovarian cancer (3 arms), sponsored by PharmaMar. Primary endpoint: Progression-free survival. Started Mar 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2014-005251-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005251-39.